Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis.
Adult
Anti-Allergic Agents
/ administration & dosage
Anti-Bacterial Agents
/ therapeutic use
Antifungal Agents
/ therapeutic use
Aspergillosis, Allergic Bronchopulmonary
/ complications
Asthma
/ complications
Canada
/ epidemiology
Cystic Fibrosis
/ complications
Female
Humans
Male
Omalizumab
/ administration & dosage
Outcome Assessment, Health Care
/ methods
Respiratory Function Tests
/ methods
Treatment Outcome
Allergic bronchopulmonary aspergillosis
Asthma
Cystic fibrosis
Omalizumab
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
ISSN: 1873-5010
Titre abrégé: J Cyst Fibros
Pays: Netherlands
ID NLM: 101128966
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
05
06
2019
revised:
15
07
2019
accepted:
31
07
2019
pubmed:
14
8
2019
medline:
23
6
2021
entrez:
14
8
2019
Statut:
ppublish
Résumé
In cystic fibrosis (CF), omalizumab has been used for difficult-to-treat asthma and allergic bronchopulmonary aspergillosis (ABPA) but safety and efficacy data are limited for this population. We assessed patients receiving omalizumab for asthma or ABPA in the Toronto adult CF center between 2005 and 2017. We evaluated treatment safety and efficacy by analyzing changes in FEV Twenty-seven CF patients received omalizumab, 16 (59.3%) for asthma and 11 (40.7%) for ABPA. No significant omalizumab-related adverse effects were observed. In the asthmatic group, the max value of FEV In adult CF patients with difficult-to-treat asthma or ABPA, omalizumab should be considered. Larger studies are needed to identify patient characteristics that may predict response to omalizumab.
Sections du résumé
BACKGROUND
In cystic fibrosis (CF), omalizumab has been used for difficult-to-treat asthma and allergic bronchopulmonary aspergillosis (ABPA) but safety and efficacy data are limited for this population.
METHODS
We assessed patients receiving omalizumab for asthma or ABPA in the Toronto adult CF center between 2005 and 2017. We evaluated treatment safety and efficacy by analyzing changes in FEV
RESULTS
Twenty-seven CF patients received omalizumab, 16 (59.3%) for asthma and 11 (40.7%) for ABPA. No significant omalizumab-related adverse effects were observed. In the asthmatic group, the max value of FEV
CONCLUSIONS
In adult CF patients with difficult-to-treat asthma or ABPA, omalizumab should be considered. Larger studies are needed to identify patient characteristics that may predict response to omalizumab.
Identifiants
pubmed: 31405730
pii: S1569-1993(19)30832-X
doi: 10.1016/j.jcf.2019.07.011
pii:
doi:
Substances chimiques
Anti-Allergic Agents
0
Anti-Bacterial Agents
0
Antifungal Agents
0
Omalizumab
2P471X1Z11
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-124Informations de copyright
Copyright © 2019 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflicts of interest to disclose.